Certified by Founder
Lodge
Delphia Therapeutics
start up
United States
- Cambridge, Massachusetts
- 07/05/2024
- Series A
- $67,000,000
Delphia Therapeutics is a biotechnology company pioneering activation lethality, a new area of cancer therapeutics that target cancer's surprising vulnerability to oncogene overactivation. Delphia’s activation lethality platform offers the potential for first-in-class targeted cancer medicines that are effective on their own while also combating the emergence of drug resistance to classic targeted therapies.
- Industry Biotechnology Research
- Website https://www.delphiatx.com/
- LinkedIn https://www.linkedin.com/company/delphia-therapeutics/
Vor Systems | $3,000,000 | (Mar 6, 2026)
IntelliGRC | $3,500,000 | (Mar 6, 2026)
Cyclops | $8,000,000 | (Mar 6, 2026)
Lio (formerly askLio) | $30,000,000 | (Mar 6, 2026)
Navigara | $2,500,000 | (Mar 6, 2026)
AgriPass | $7,500,000 | (Mar 6, 2026)
Reclaim Security | $20,000,000 | (Mar 6, 2026)
NextWork | $4,450,000 | (Mar 6, 2026)
Vast | $500,000,000 | (Mar 6, 2026)
Qura | $1,739,595 | (Mar 4, 2026)
Escargot | $2,750,000 | (Mar 4, 2026)
Worldscape | Undisclosed Amount | (Mar 4, 2026)